Bring a new drug to market is not easy and one that addresses rare diseases may be even harder. Stoke Therapeutics, based in Bedford, Massachusetts, is attempting to tackle a complex and catastrophic disease – Dravet Syndrome – that attacks in the first year of life causing epilepsy-type seizures, and a whole host of behavioral and cognitive challenges.
In this podcast, Barry Ticho, the company’s chief medical officer explains what the therapy the company is developing and how it may alleviate the symptoms of the disease.
